Research Article
A Single High-Sensitivity Cardiac Troponin T Strategy for Ruling Out Myocardial Infarction
Table 1
Baseline patient characteristics.
| | Total | Derivation cohort | Validation cohort 1 | Validation cohort 2 | | N = 24973 | N = 132021 | N = 1138 |
| | Demographics | | Age (y) | 61.0 (46.0–74.0) | 56.6 (41.8–70.8) | 63.1 (48.9–73.7) | | Men | 12957 (51.9%) | 67841 (51.4%) | 638 (54.7%) | | Women | 12016 (48.1%) | 64180 (48.6%) | 529 (45.3%) | | Arrival by ambulance | 8662 (34.7%) | 30741 (23.2%) | 476 (40.8%) | | Past medical history | | Hypertension | 5666 (22.7%) | 29050 (22%) | 506 (43.4%) | | Hyperlipidemia | 1282 (5.1%) | 12012 (9.1%) | 262 (22.5%) | | Diabetes | 3535 (14.2%) | 11195 (8.4%) | 162 (13.9%) | | History of CAD | 3924 (15.7%) | 13658 (10.3%) | 333 (28.5%) | | History of AMI | 2647 (10.6%) | 9831 (7.5%) | 235 (20.1%) | | History of stroke/TIA | 1812 (7.3%) | 5245 (4.0%) | 105 (9.0%) | | COPD | 1058 (4.2%) | 4384 (3.3%) | 88 (7.5%) | | In-hospital characteristics | | GFR <60 mL/min/1.73 m2 | 3172 (12.7%) | 15001 (11.4%) | 176 (15.1%) | | Time to hs-cTnT sample <60 min | 19444 (77.9%) | 107077 (81.1%) | NA | | Time to hs-cTnT sampling (min) | 34.0 (20–57) | 26 (13–48) | NA | | Medications at presentation | | ACE-I/ARB | 6323 (25.3%) | 32341 (24.5%) | 364 (31.2%) | | Aspirin | 4261 (17.1%) | 22526 (17.1%) | 351 (30.1%) | | Statin | 5578 (22.3%) | 24120 (18.3%) | 349 (29.9%) | | Beta-blocker | 3380 (13.5%) | 30363 (23.0%) | 355 (30.4%) | | Diuretics | 4091 (16.4%) | 15749 (11.9%) | 239 (20.5%) | | Nitroglycerine | 1551 (6.2%) | 8889 (6.7%) | 269 (23.1%) | | NOAC/Warfarin | 1736 (6.9%) | 8351 (6.3%) | 116 (9.9%) | | P2Y12 inhibitor | 931 (3.7%) | 3658 (2.8%) | 81 (6.9%) | | Outcomes | | AMI/death within 30 days | 1668 (6.7%) | 7668 (5.8%) | 93 (8.0%) | | AMI 30 days | 1458 (5.8%) | 6924 (5.2%) | 89 (7.6%) | | Death within 30 days | 264 (1.1%) | 1045 (0.8%) | 5 (0.4%) | | Death within 365 days | 1210 (4.8%) | 4888 (3.7%) | NA |
|
|
Values are the median (25th percentile and 75th percentile) or n (%). ACEi: ACE inhibitors; AMI: acute myocardial infarction; ARB: angiotensin receptor blockers; CAD: coronary artery disease; COPD: chronic obstructive pulmonary disease; GFR: glomerular filtration rate (MDRD 4); Hs-cTnT: high-sensitive cardiac troponin T; NOAC: novel oral anticoagulants; STEMI: ST-elevation myocardial infarction; TIA: transient ischemic attack.
|
